Sana Biotechnology
SANA
147 hedge funds and large institutions have $810M invested in Sana Biotechnology in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 27 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 36
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0.57% more ownership
Funds ownership: 66.38% → 66.94% (+0.57%)
5% less funds holding
Funds holding: 154 → 147 (-7)
19% less call options, than puts
Call options by funds: $6.73M | Put options by funds: $8.35M
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
45% less capital invested
Capital invested by funds: $1.46B → $810M (-$653M)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.9M |
| 2 |
BlackRock
New York
|
+$15.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.77M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$4.91M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.78M |
Top Sellers
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$25.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$14.6M |
| 3 |
DFO
Duquesne Family Office
New York
|
-$9.84M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$5.44M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.6M |
SANA Hedge Fund Activity: Q2 2024 in Review
147 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q2 2024, worth a combined $810M — down 45% from $1.46B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of SANA and 21 opened new positions — a net loss of 6 holders — while 36 trimmed existing stakes and 58 added.
The largest buyer was Fidelity Investments, adding an estimated $40.9M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $25.8M.
- 147 institutional investors held Sana Biotechnology (SANA) as of Q2 2024, down from 154 in Q1 2024.
- Funds reported $810M of Sana Biotechnology stock for Q2 2024, down 45% quarter-over-quarter.
- 21 funds opened new Sana Biotechnology positions in Q2 2024 and 27 closed out, a net change of -6 holders.
- The largest Sana Biotechnology buyer in Q2 2024 was Fidelity Investments, an estimated $40.9M added.
- The largest Sana Biotechnology seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $25.8M sold.
Based on aggregated 13F filings for Q2 2024.